LIVIVO - Das Suchportal für Lebenswissenschaften

switch to English language
Erweiterte Suche

Ihre letzten Suchen

  1. AU="Eisinger, Felix"
  2. AU="van Arkel, Gijs H J"
  3. AU="Dukkipati, Haripriya"
  4. AU="Mansoor, Farheen"
  5. AU="Stanton, Clive"
  6. AU=Herholz K AU=Herholz K
  7. AU="Marichal, Axel"
  8. AU="Camon, Ana M"
  9. AU="Randall, Michael D"

Suchergebnis

Treffer 1 - 9 von insgesamt 9

Suchoptionen

  1. Artikel ; Online: 60-jähriger Mann mit unklarer Proteinurie und auffälligen Strukturen in der Niere.

    Eisinger, Felix / Artunc, Ferruh / Bohnert, Bernhard N

    Deutsche medizinische Wochenschrift (1946)

    2023  Band 148, Heft 19, Seite(n) 1225–1226

    Titelübersetzung 60-year-old man with proteinuria of unknown origin and unusual structures in the kidney.
    Mesh-Begriff(e) Male ; Humans ; Middle Aged ; Kidney/diagnostic imaging ; Proteinuria/etiology
    Sprache Deutsch
    Erscheinungsdatum 2023-10-04
    Erscheinungsland Germany
    Dokumenttyp Case Reports ; Journal Article
    ZDB-ID 200446-x
    ISSN 1439-4413 ; 0012-0472
    ISSN (online) 1439-4413
    ISSN 0012-0472
    DOI 10.1055/a-2088-0616
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  2. Buch ; Online ; Dissertation / Habilitation: Thrombozyten-induzierte Apoptose – Rolle der thrombozytären Adhäsionsrezeptoren

    Eisinger, Felix [Verfasser]

    2020  

    Verfasserangabe Felix Eisinger
    Schlagwörter Medizin, Gesundheit ; Medicine, Health
    Thema/Rubrik (Code) sg610
    Sprache Deutsch
    Verlag Universitätsbibliothek Tübingen
    Erscheinungsort Tübingen
    Dokumenttyp Buch ; Online ; Dissertation / Habilitation
    Datenquelle Digitale Dissertationen im Internet

    Zusatzmaterialien

    Kategorien

  3. Artikel: 60-jähriger Mann mit unklarer Proteinurie und auffälligen Strukturen in der Niere

    Eisinger, Felix / Artunc, Ferruh / Bohnert, Bernhard N.

    DMW - Deutsche Medizinische Wochenschrift

    2023  Band 148, Heft 19, Seite(n) 1225–1226

    Sprache Deutsch
    Erscheinungsdatum 2023-09-01
    Verlag Georg Thieme Verlag KG
    Erscheinungsort Stuttgart ; New York
    Dokumenttyp Artikel
    ZDB-ID 200446-x
    ISSN 1439-4413 ; 0012-0472
    ISSN (online) 1439-4413
    ISSN 0012-0472
    DOI 10.1055/a-2088-0616
    Datenquelle Thieme Verlag

    Zusatzmaterialien

    Kategorien

  4. Artikel ; Online: The Mutual Relation of Platelet Activation and Innate Immunity.

    Eisinger, Felix / Langer, Harald F

    Hamostaseologie

    2018  Band 38, Heft 4, Seite(n) 186–202

    Abstract: Platelets are known to be central regulators of haemostasis, inflammation and immune response. Formed by megakaryocytes in the bone marrow and the lungs, platelets express a broad range of adhesion ... ...

    Abstract Platelets are known to be central regulators of haemostasis, inflammation and immune response. Formed by megakaryocytes in the bone marrow and the lungs, platelets express a broad range of adhesion receptors
    Mesh-Begriff(e) Animals ; Blood Platelets/immunology ; Complement System Proteins/immunology ; Humans ; Immunity, Innate ; Infection/immunology ; Inflammation/immunology ; Neoplasms/immunology ; Platelet Activation
    Chemische Substanzen Complement System Proteins (9007-36-7)
    Sprache Englisch
    Erscheinungsdatum 2018-09-25
    Erscheinungsland Germany
    Dokumenttyp Journal Article ; Review
    ZDB-ID 801512-0
    ISSN 2567-5761 ; 0720-9355
    ISSN (online) 2567-5761
    ISSN 0720-9355
    DOI 10.1055/s-0038-1669450
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  5. Artikel ; Online: Standardized, risk-adapted induction therapy in kidney transplantation.

    Eisinger, Felix / Mühlbacher, Thomas / Na, Ario / Althaus, Karina / Nadalin, Silvio / Birkenfeld, Andreas L / Heyne, Nils / Guthoff, Martina

    Journal of nephrology

    2023  Band 36, Heft 7, Seite(n) 2133–2138

    Abstract: Background: The choice of induction therapy in kidney transplantation is often non-standardized and centre-specific. Clinicians can choose between depleting and non-depleting antibodies, which differ in their immunosuppressive capacity and the ... ...

    Abstract Background: The choice of induction therapy in kidney transplantation is often non-standardized and centre-specific. Clinicians can choose between depleting and non-depleting antibodies, which differ in their immunosuppressive capacity and the concomitant risk of infection. We herein present a standardized risk-stratified algorithm for induction therapy that might help to balance the risk of rejection and/or serious infection.
    Methods: Prior to kidney transplantation, patients were stratified into low-risk, intermediate-risk or high-risk according to our protocol based on immunologic risk factors. Depending on their individual immunologic risk, patients received basiliximab (low risk), antithymocyte globulin (intermediate risk) or low-dose alemtuzumab (high risk) for induction therapy. We analysed the results after 3 years of implementation of our risk-stratified induction therapy protocol at our kidney transplant centre.
    Results: Between 01/2017 and 05/2020, 126 patients were stratified in accordance with our protocol (low risk/intermediate risk/high risk: 69 vs. 42 vs. 15 patients). The median follow-up time was 1.9 [1.0-2.5] years. No significant difference was observed in rejection rate and allograft survival (low risk/intermediate risk/high risk: 90.07% vs. 80.81% vs. 100% after 3 years (p > 0.05)) among the groups. The median eGFR at follow-up was (low risk/intermediate risk/high risk) 47 [33-58] vs 58 [46-76] vs 44 [22-55] ml/min/1.73 m
    Conclusions: Our strategy offers facilitated and individualized choice of induction therapy in kidney transplantation. We propose further evaluation of our algorithm in prospective trials.
    Mesh-Begriff(e) Humans ; Alemtuzumab/adverse effects ; Kidney Transplantation/adverse effects ; Antibodies, Monoclonal, Humanized/adverse effects ; Prospective Studies ; Induction Chemotherapy/adverse effects ; Immunosuppressive Agents/therapeutic use ; Graft Rejection ; Graft Survival
    Chemische Substanzen Alemtuzumab (3A189DH42V) ; Antibodies, Monoclonal, Humanized ; Immunosuppressive Agents
    Sprache Englisch
    Erscheinungsdatum 2023-09-09
    Erscheinungsland Italy
    Dokumenttyp Journal Article
    ZDB-ID 1093991-x
    ISSN 1724-6059 ; 1120-3625 ; 1121-8428
    ISSN (online) 1724-6059
    ISSN 1120-3625 ; 1121-8428
    DOI 10.1007/s40620-023-01746-1
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  6. Artikel ; Online: SGLT2 Inhibitors Decrease Overhydration and Proteasuria in Patients with Chronic Kidney Disease: A Longitudinal Observational Study.

    Schork, Anja / Eberbach, Marie-Luise / Bohnert, Bernhard N / Wörn, Matthias / Heister, David J / Eisinger, Felix / Vogel, Elisabeth / Heyne, Nils / Birkenfeld, Andreas L / Artunc, Ferruh

    Kidney & blood pressure research

    2024  Band 49, Heft 1, Seite(n) 124–134

    Abstract: Introduction: SGLT2 inhibitors are used to reduce the risk of progression of chronic kidney disease (CKD). In patients with type 2 diabetes, they have been found to reduce extracellular volume. Given the high prevalence of extracellular volume expansion ...

    Abstract Introduction: SGLT2 inhibitors are used to reduce the risk of progression of chronic kidney disease (CKD). In patients with type 2 diabetes, they have been found to reduce extracellular volume. Given the high prevalence of extracellular volume expansion and overhydration (OH) in CKD, we investigated whether SGLT2 inhibitors might correct these disturbances in CKD patients.
    Methods: CKD patients who started treatment with an SGLT2 inhibitor were investigated in this prospective observational study for 6 months. Body composition and fluid status were measured by bioimpedance spectroscopy. In addition, spot urine samples were analyzed for albuminuria, glucosuria, and urinary aprotinin-sensitive serine protease activity.
    Results: Forty-two patients (29% with diabetic/hypertensive CKD, 31% with IgA nephropathy; 88% dapagliflozin 10 mg, 10% dapagliflozin 5 mg, 2% empagliflozin 20 mg; median eGFR 46 mL/min/1.73 m2 and albuminuria 1,911 mg/g creatinine) participated in the study. Median glucosuria increased to 14 (10-19) g/g creatinine. At baseline, patients displayed OH with +0.4 (-0.2 to 2.2) L/1.73 m2, which decreased by 0.5 (0.1-1.2) L/1.73 m2 after 6 months. Decrease of OH correlated with higher OH at BL, decrease of albuminuria, glucosuria, and urinary aprotinin-sensitive protease activity. Adipose tissue mass was not significantly reduced after 6 months.
    Conclusion: SGLT2 inhibitors reduce OH in patients with CKD, which is pronounced in the presence of high albuminuria, glucosuria, and urinary aprotinin-sensitive protease activity.
    Mesh-Begriff(e) Humans ; Sodium-Glucose Transporter 2 Inhibitors/therapeutic use ; Sodium-Glucose Transporter 2 Inhibitors/pharmacology ; Renal Insufficiency, Chronic/drug therapy ; Renal Insufficiency, Chronic/urine ; Male ; Female ; Middle Aged ; Aged ; Longitudinal Studies ; Glucosides/therapeutic use ; Glucosides/pharmacology ; Benzhydryl Compounds/therapeutic use ; Benzhydryl Compounds/pharmacology ; Prospective Studies ; Serine Proteases ; Diabetes Mellitus, Type 2/drug therapy ; Diabetes Mellitus, Type 2/complications
    Chemische Substanzen Sodium-Glucose Transporter 2 Inhibitors ; Glucosides ; Benzhydryl Compounds ; dapagliflozin (1ULL0QJ8UC) ; empagliflozin (HDC1R2M35U) ; Serine Proteases (EC 3.4.-)
    Sprache Englisch
    Erscheinungsdatum 2024-01-16
    Erscheinungsland Switzerland
    Dokumenttyp Journal Article ; Observational Study
    ZDB-ID 1326018-2
    ISSN 1423-0143 ; 1420-4096
    ISSN (online) 1423-0143
    ISSN 1420-4096
    DOI 10.1159/000535643
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  7. Artikel: The Mutual Relation of Platelet Activation and Innate Immunity

    Eisinger, Felix / Langer, Harald F.

    Hämostaseologie

    2018  Band 38, Heft 04, Seite(n) 186–202

    Abstract: Platelets are known to be central regulators of haemostasis, inflammation and immune response. Formed by megakaryocytes in the bone marrow and the lungs, platelets express a broad range of adhesion receptors and release cytokines and platelet ... ...

    Abstract Platelets are known to be central regulators of haemostasis, inflammation and immune response. Formed by megakaryocytes in the bone marrow and the lungs, platelets express a broad range of adhesion receptors and release cytokines and platelet microparticles which enable them to interact with both immune cells and pathogens. In bacterial and viral infections, thrombophilia and thrombocytopenia are commonly seen symptoms, indicating the close relationship between haemostasis and immune defence. Indeed, platelets contribute both directly and via immune mediation to pathogen clearance. In sterile inflammation, a pathogen-free process which is often triggered by cell necrosis and autoimmune reactions, platelets are also of central importance. Recently, platelet inflammasome has been extensively studied in this context. Both sterile inflammation and infection are affected by the interactions of platelets and innate immunity, notably the complement system. Although the general elements of this interplay have been known for long, more and more insights into disease-specific mechanisms could be gained recently. This review gives an outline of the current findings in the field of platelet–immune cell interactions and points out possible implications for clinical therapy.
    Schlagwörter platelets ; innate immunity ; inflammation ; infection ; cytokines ; inflammasome ; leukocytes ; complement system ; Blutplättchen ; angeborene Immunität ; Entzündung ; Infektion ; Zytokine ; Inflammasom ; Leukozyten ; Komplementsystem
    Sprache Englisch
    Erscheinungsdatum 2018-09-25
    Verlag Georg Thieme Verlag KG
    Erscheinungsort Stuttgart ; New York
    Dokumenttyp Artikel
    ZDB-ID 801512-0
    ISSN 2567-5761 ; 0720-9355
    ISSN (online) 2567-5761
    ISSN 0720-9355
    DOI 10.1055/s-0038-1669450
    Datenquelle Thieme Verlag

    Zusatzmaterialien

    Kategorien

  8. Artikel: The Platelet Response to Tissue Injury.

    Eisinger, Felix / Patzelt, Johannes / Langer, Harald F

    Frontiers in medicine

    2018  Band 5, Seite(n) 317

    Abstract: In recent years, various studies have increasingly explained platelet functions not only in their central role as a regulator in cellular hemostasis and coagulation. In fact, there is growing evidence that under specific conditions, platelets act as a ... ...

    Abstract In recent years, various studies have increasingly explained platelet functions not only in their central role as a regulator in cellular hemostasis and coagulation. In fact, there is growing evidence that under specific conditions, platelets act as a mediator between the vascular system, hemostasis, and the immune system. Therefore, they are essential in many processes involved in tissue remodeling and tissue reorganization after injury or inflammatory responses. These processes include the promotion of inflammatory processes, the contribution to innate and adaptive immune responses during bacterial and viral infections, the modulation of angiogenesis, and the regulation of cell apoptosis in steady-state tissue homeostasis or after tissue breakdown. All in all platelets may contribute to the control of tissue homeostasis much more than generally assumed. This review summarizes the current knowledge of platelets as part of the tissue remodeling network and seeks to provide possible translational implications for clinical therapy.
    Sprache Englisch
    Erscheinungsdatum 2018-11-13
    Erscheinungsland Switzerland
    Dokumenttyp Journal Article ; Review
    ZDB-ID 2775999-4
    ISSN 2296-858X
    ISSN 2296-858X
    DOI 10.3389/fmed.2018.00317
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  9. Artikel ; Online: Late Onset Cerebral Nocardiosis in a Sensitized Renal Transplant Recipient Following Alemtuzumab Induction: A Case Report.

    Eisinger, Felix / Walter, Elias / Nadalin, Silvio / Birkenfeld, Andreas L / Heyne, Nils / Guthoff, Martina / Mühlbacher, Thomas

    Transplantation proceedings

    2021  Band 54, Heft 1, Seite(n) 116–119

    Abstract: Background: Balancing immunosuppressive regimen to prevent rejection yet avoiding severe infectious complications remains a key challenge following renal transplantation, especially in patients sensitized after exposure to human leukocyte antigens. We ... ...

    Abstract Background: Balancing immunosuppressive regimen to prevent rejection yet avoiding severe infectious complications remains a key challenge following renal transplantation, especially in patients sensitized after exposure to human leukocyte antigens. We herein report a late onset infection with nocardia in a sensitized renal transplant recipient.
    Case presentation: A 65-year-old male patient, who had received kidney transplantation with alemtuzumab induction due to human leukocyte antigen-sensitization 3 years ago, was admitted with headache and dizziness. A cerebral magnetic resonance imaging scan showed a right parieto-occipital brain abscess. Surgical abscess drainage was performed and microbiology analysis detected Nocardia paucivorans in the abscess fluid. Laboratory results showed persistently reduced lymphocyte and T-cell counts 3 years after transplantation. We started intravenous antibiotic therapy with high dose trimethoprim/sulfamethoxazole and imipenem/cilastatin. Furthermore, immunosuppression was adapted with discontinuation of mycophenolate. After 7 weeks of intravenous antibiotic therapy, the patient was switched to an oral antibiotic regimen with amoxicillin/clavulanic acid and minocycline. In the follow-up magnetic resonance imaging scan, cerebral lesions were substantially reduced, initial symptoms completely disappeared, and allograft function remained stable.
    Conclusions: Induction therapy with the CD52-antibody alemtuzumab enables transplantation in highly sensitized patients but leads to lymphocyte depletion for several weeks. Our patient presented with prolonged lymphopenia and a significantly reduced T-cell count 3 years after transplantation. To our knowledge, our case is the first to describe a late-onset nocardia infection 3 years after alemtuzumab induction in a renal transplant recipient. It underlines the importance of considering this rare disease in transplant patients, especially after induction therapy with depleting antibodies.
    Mesh-Begriff(e) Aged ; Alemtuzumab ; Graft Rejection ; Humans ; Immunosuppressive Agents/adverse effects ; Kidney Transplantation/adverse effects ; Male ; Nocardia Infections/diagnosis ; Nocardia Infections/drug therapy
    Chemische Substanzen Immunosuppressive Agents ; Alemtuzumab (3A189DH42V)
    Sprache Englisch
    Erscheinungsdatum 2021-12-30
    Erscheinungsland United States
    Dokumenttyp Case Reports
    ZDB-ID 82046-5
    ISSN 1873-2623 ; 0041-1345
    ISSN (online) 1873-2623
    ISSN 0041-1345
    DOI 10.1016/j.transproceed.2021.10.014
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

Zum Seitenanfang